Our research illustrated that increased calcium/cathepsin B activation/trypsinogen activation might be one of the mechanisms underlying acute pancreatitis induced by the proteasome inhibitor Bortezomib or Ixazomib in patients with multiple myeloma. The gene discussed is CTSB; the disease is acute pancreatitis.